Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Liabilities and Shareholders Equity (2021 - 2025)

Verrica Pharmaceuticals has reported Liabilities and Shareholders Equity over the past 5 years, most recently at $47.1 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $47.1 million for Q4 2025, down 12.94% from a year ago — trailing twelve months through Dec 2025 was $169.3 million (down 17.56% YoY), and the annual figure for FY2025 was $47.1 million, down 12.94%.
  • Liabilities and Shareholders Equity for Q4 2025 was $47.1 million at Verrica Pharmaceuticals, up from $40.9 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for VRCA hit a ceiling of $108.1 million in Q1 2021 and a floor of $32.9 million in Q3 2024.
  • Median Liabilities and Shareholders Equity over the past 5 years was $62.8 million (2022), compared with a mean of $64.5 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 97.67% in 2023 and later plummeted 66.11% in 2024.
  • Verrica Pharmaceuticals' Liabilities and Shareholders Equity stood at $80.1 million in 2021, then crashed by 44.19% to $44.7 million in 2022, then surged by 82.46% to $81.6 million in 2023, then plummeted by 33.66% to $54.1 million in 2024, then dropped by 12.94% to $47.1 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $47.1 million (Q4 2025), $40.9 million (Q3 2025), and $39.1 million (Q2 2025) per Business Quant data.